Services PMI® at 51.6%; April 2025 Services ISM® Report On Business®
Business Activity Index at 53.7%; New Orders Index at 52.3%; Employment Index at 49%; Supplier Deliveries Index at 51.3% TEMPE,...
Coronavirus
Manufacturing PMI® at 48.7%; April 2025 Manufacturing ISM® Report On Business®
New Orders and Backlogs Contracting; Production and Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Growing; Customers' Inventories Too Low...
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and...
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge...
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO,...
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,...
Universal Life Selects Sapiens to Modernise its Core Systems
Sapiens' solution will accelerate Universal Life's growth and efficiency ROCHELLE PARK, N.J., April 15, 2025 /PRNewswire/ -- Sapiens International Corporation (NASDAQ:...
Glass House Brands Announces Hemp Research and Development Agreement with the University of California, Berkeley
LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")...
Services PMI® at 50.8%; March 2025 Services ISM® Report On Business®
Business Activity Index at 55.9%; New Orders Index at 50.4%; Employment Index at 46.2%; Supplier Deliveries Index at 50.6% TEMPE,...
Aligos Therapeutics Presents Positive Data at APASL 2025
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3),...
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc....
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart,...
Services PMI® at 53.5%; February 2025 Services ISM® Report On Business®
Business Activity Index at 54.4%; New Orders Index at 52.2%; Employment Index at 53.9%; Supplier Deliveries Index at 53.4% TEMPE, Ariz., March...
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
Aligos Therapeutics Announces $105 Million Private Placement Financing
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into...
Services PMI® at 52.8%; January 2025 Services ISM® Report On Business®
Business Activity Index at 54.5%; New Orders Index at 51.3%; Employment Index at 52.3%; Supplier Deliveries Index at 53%; This...
XORTX to Present at Microcap Conference
CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...